PUBLISHER: 360iResearch | PRODUCT CODE: 1375472
PUBLISHER: 360iResearch | PRODUCT CODE: 1375472
The Biobanking Market is projected to reach USD 152.75 billion by 2030 from USD 63.45 billion in 2022, at a CAGR of 11.60% during the forecast period.
Global Biobanking Market
KEY MARKET STATISTICS | |
---|---|
Base Year Value [2022] | USD 63.45 billion |
Estimated Year Value [2023] | USD 70.33 billion |
Forecast Year Value [2030] | USD 152.75 billion |
CAGR (%) | 11.60% |
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biobanking Market.
Based on Product, market is studied across Consumables, Equipment & Instruments, Services, and Software. The Services is projected to witness significant market share during forecast period.
Based on Sample Type, market is studied across Biological Fluids, Blood Products, Cell Lines, Human Tissues, and Nucleic Acids. The Biological Fluids is projected to witness significant market share during forecast period.
Based on Storage Type, market is studied across Automated and Manual. The Automated is projected to witness significant market share during forecast period.
Based on Application, market is studied across Clinical Research, Life Science Research, and Regenerative Medicine. The Regenerative Medicine is projected to witness significant market share during forecast period.
Based on End-User, market is studied across Academic & Research Institutes, Hospitals, and Pharmaceutical & Biotechnology. The Hospitals is projected to witness significant market share during forecast period.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 37.91% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
The FPNV Positioning Matrix is an indispensable tool for assessing the Biobanking Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
The Market Share Analysis offers invaluable insights into the vendor landscape Biobanking Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
The report delves into recent significant developments in the Biobanking Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology (Europe) Limited, ASKION GmbH, Avantor, Inc., Azenta Life Sciences, Bay Biosciences LLC, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, Merck KgaA, Micronic Holding B.V., PHC Holdings Corporation, Promega Corporation, ProteoGenex, QIAGEN N.V., Sopachem NV/SA, SPT Labtech Ltd., STEMCELL Technologies Inc., Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., UK Biobank Limited, and US Biolab Corporation, Inc..
1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast for the Biobanking Market?
2. Which products, segments, applications, and areas hold the highest investment potential in the Biobanking Market?
3. What is the competitive strategic window for identifying opportunities in the Biobanking Market?
4. What are the latest technology trends and regulatory frameworks in the Biobanking Market?
5. What is the market share of the leading vendors in the Biobanking Market?
6. Which modes and strategic moves are suitable for entering the Biobanking Market?